All In Biotech

Drug Trial Radar · NCT02626299

Assessment of DHA On Reducing Early Preterm Birth

Assessment of DHA On Reducing Early Preterm Birth (ADORE Trial)

Last checked: Nov 19, 2026Latest source record: Mar 30, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,100

Actual

Start

Jun 8, 2016

Primary completion

Oct 5, 2020

Study completion Oct 5, 2020

Sponsor

Lead sponsor
University of Kansas Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Cincinnati; Ohio State University; Nationwide Children's Hospital
First posted
Dec 10, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
Female only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if giving a larger amount of DHA than currently included in some prenatal supplements can reduce early preterm birth (birth before 34 weeks of pregnancy).

Conditions

  • Preterm Birth

Interventions

  • Docosahexaenoic acid - 800mg/dayDrug

    All participants will take 1000 mg/DHA per day (1 capsule will be labeled with 200 mg; 2 capsules will be masked with 400 mg each)

  • Docosahexaenoic acid - 200mg/dayDrug

    The control group will receive 1-capsule containing 200 mg DHA/d.

  • PlaceboOther

    Participants will receive 2 capsules (masked) containing half soybean oil and half corn oil equaling 800 mg.The soybean and corn oil combination does not contain DHA.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of Early Preterm Birth (<34 weeks gestation)Time frame: Baseline to 34 Weeks
  2. Occurrence of Early Preterm Birth (<34 weeks gestation)Time frame: Baseline to 34 weeks
  3. Maternal and infant adverse and serious adverse eventsTime frame: Enrollment to 30 days past last birth

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • University of Kansas Medical Center

    Kansas City, Kansas

  • University of Cincinnati

    Cincinnati, Ohio

  • Ohio State University

    Columbus, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.